lucius卢修斯沃拉西地尼 Vorasidenib全球首仿

沃拉西地尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Vorasidenib

老挝国家食药监局批准上市
老挝国家药检所检测认证
全球首仿

Compasitina:
ach film-coated tablet contains Vorasidenib

LUCIUS
PHARMACEUTICALS

Indication:

星形细胞瘤

LuciVora is an isocitrate debydrogenase-1 (IDI1
and isocitrate debydrogenase-2(IDH2)inhibitot
indicated for the treatment of adult and nedintrie

LuciVora

Palcila 14 ycars and older with cavde

nd older wita Grade z astrocyto
T sasceptible IDHI or
Ayilh a suscentible IDHL nr

e wwanww enuwing sergery inciuding biops
sub-totel resection, or pross total resection
ry ineludine hiane
Desage and Use:
.Recommended dosage in adults: 40 mg orally once

Vorasidenib Tablets

胶质细胞瘤

*Recommended dosage in pediatrie patients 12 vears
*Kecommended dosag
of age and older based on body weight: 240 kg: 40 mp

40mg

orally osce daily

g.0 mg orallv onse dsly

. Take with or without food.
slorage: in a dry place and store at 20C to 25°C.
Warning:

30 Tablets

Keep medicine out of reach of Childeen, Do set
nister LuciVora during Pregnancy and Lactation
PLEASE SEE PACKAGE INSERT

FDA批准

Manufactured and Marketed by:
LUCIUS

Thongmang village. Xaythany distris
Vientiane Capital, LaoS

权威认证

Warning: lo be sold by retail on prescription
pysacians only, and as directed

Rx Only

口碑质量

适应症:

沃拉西地尼是一种异柠檬酸脱氢酶1(IDH1)和异柠檬酸脱氢酶2(IDH2)
抑制剂,用于治疗12岁及以上的成人和儿童患者,这些患者在手术(包
括活检、次全切除或全切除)后患有2级星形细胞瘤或少突胶质细胞瘤,
且存在易感IDH1或IDH2突变。
推荐剂量:

1、成人:每日口服一次,每次40mg。
2、12岁及以上儿童患者的推荐剂量:
·≥40公斤:每日口服一次,每次40mg;
·< 40公斤:每日口服一次,每次20mg。

3、随餐服用或空腹服用均可。